Supplementary materials: Cost–effectiveness analysis of prolonged-release fampridine to treat walking disability of multiple sclerosis in China

dataset

posted on 2024-05-03, 14:30 authored by Xinran Zhao, Han Yang, Tian Wei, Jin Zhao, Jun Li, Zhe Huang, Lin Zhu, Yinan Zhao, Wei Li

These are peer-reviewed supplementary materials for the article 'Cost–effectiveness analysis of prolonged-release fampridine to treat walking disability of multiple sclerosis in China' published in the Journal of Comparative Effectiveness Research.<ol><li>Symptomatic medications and duration of treatment in multiple sclerosis (MS) adult patients with walking disability (EDSS [expanded disability status scale] score 4-7)</li><li>Frequency and duration of rehabilitation therapy in MS adult patients with walking disability (EDSS score 4-7)</li><li>Healthcare resource utilization in the treatment of MS adult patients with walking disability (EDSS score 4-7)</li><li>The relationship between walking ability and costs</li><li>Supplementary Table 1 EQ-5D-5L utilities from the ENHANCE and MOBILE trial</li></ol>Objectives: This study evaluates the cost–effectiveness of adding prolonged-release (PR)-fampridine to best supportive care (BSC) versus BSC alone in adult multiple sclerosis patients with walking disability in China. Materials & methods: A hybrid decision tree and Markov model from both the societal and healthcare perspectives were constructed. Parameters were derived from clinical trials of PR-fampridine, published sources and clinical expert interviews. Results: Over a 10-year time horizon, adding PRfampridine to BSC led to 0.15 quality-adjusted life year (QALY) gain and lower costs,with incremental cost–effectiveness ratios of -238,806 Chinese Yuan/QALY and -113,488 Chinese Yuan/QALY from the societal and healthcare perspectives, respectively. Conclusion: Compared with BSC alone, PR-fampridine plus BSC is considered an economically dominant strategy for the treatment of multiple sclerosis-related walking disability in China.